MediPharm Labs Appoints Renowned Medical Expert and Pharmaceutical Researcher Dr. Paul Tam to its Board of Directors
01 Mai 2019 - 12:30PM
MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MEDIF) (FSE: MLZ)
(“MediPharm Labs” or the “Company”) a global leader in specialized,
research-driven cannabis extraction, distillation, purification and
cannabinoid isolation, is pleased to announce the appointment of
Dr. Paul Tam, MBBS, FRCP(C), FACP to its Board of Directors
effective immediately, subject to the necessary regulatory
approvals. In connection with the Company’s goal of satisfying
non-venture requirements for corporate governance and financial
oversight, Dr. Tam will also replace Chris Hobbs on the Company’s
Audit Committee resulting in an Audit Committee fully comprised of
independent directors in accordance with National Instrument 52-110
– Audit Committees.
“Dr. Paul Tam is a tremendous addition to our
board and will be a valuable independent director and contributor
as we continue to deepen our medical expertise through this next
phase of growth,” said Patrick McCutcheon, Chief Executive Officer,
MediPharm Labs. “Dr. Tam brings significant pedigree and experience
in his field and from his tenure with leading pharmaceutical
companies. We look forward to benefiting from his guidance as we
focus on advancing initiatives for the commercial development of
high quality, pharmaceutical-like cannabinoid-based products and
active pharmaceutical ingredients for a rapidly growing medical and
adult-use market.”
With more than three decades of clinical
research and medical practice experience, Dr. Paul Tam is a
globally recognized expert in the field of nephrology and a pioneer
in the development of continuous renal replacement therapy for
acute kidney injury. In 1996, Dr. Tam founded the Scarborough
Regional Nephrology Program where he is currently Medical Director
of the largest community nephrology program in Canada. Dr. Tam
oversees a team of thirteen nephrologists that provide renal care
to over 900 dialysis patients and 4,000 chronic kidney disease
patients and is also an active staff nephrologist at The
Scarborough Hospital. Dr. Tam is also the Medical Quality Advisor
for three major Independent Health Facilities that provide
hemodialysis care.
Dr. Tam has extensive and highly specialized
experience in pharmaceutical development having co-founded and
acted as the Medical Director overseeing operations and clinical
research for a contract research organization which was ultimately
acquired by the Biovail Corporation. Dr. Tam served as a Director
of Biovail Corporation after the acquisition and he also served as
the Medical Director of Contract Research arm of Biovail
Corporation. Dr. Tam continues to be active in clinical research
and participate in multi-national trials, product commercialization
and is a highly respected subject matter author.
“I’m grateful for the opportunity to join
MediPharm Labs’ Board of Directors as the Company continues to lead
the way in a brand-new industry that has shown incredible potential
to improve people’s lives,” said Dr. Paul Tam. “I look forward
to working with the Board and management team to help grow and
shape the future of MediPharm Labs as it focuses on developing
cannabis-based derivative products in a rapidly expanding global
industry.”
Dr. Tam also leads and serves on multiple
professional and executive governance committees. He is an
active member and past Section Chair representing the Nephrology
Specialty of the Ontario Medical Association, and active member and
past Chair of the Ontario Association of Nephrologists. In
the past he has also served on the Boards of Directors for
pharmaceutical companies.
Dr. Tam received his medical degree from The
University of Hong Kong and completed further specialization at the
University of Toronto, Canada.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs has the
distinction of being the first company in Canada to become a
licensed producer for cannabis oil production under the ACMPR
without first receiving a cannabis cultivation licence. This expert
focus on cannabis concentrates from being built to cGMP (current
Good Manufacturing Practices) and ISO standard-built clean rooms
and critical environments laboratory, allows MediPharm Labs to
produce purified, pharmaceutical-like cannabis oil and concentrates
for advanced derivative products. MediPharm Labs has invested in an
expert, research-driven team, state-of-the-art technology,
downstream extraction methodologies and purpose-built facilities to
deliver pure, safe and precisely-dosed cannabis products to
patients and consumers. MediPharm Labs’ private label program is a
high margin business for the Company, whereby it opportunistically
procures dry cannabis flower and trim from its numerous product
supply partners, to produce cannabis oil concentrate products for
resale globally on a private label basis.
Through its subsidiary, MediPharm Labs Australia
Pty. Ltd., MediPharm Labs has also completed its application
process with the federal Office of Drug Control to extract and
import medical cannabis products in Australia.
For further information, please
contact: Investor Relations &
Communications Telephone: 705-719-7425 ext 216 Email:
investors@medipharmlabs.com Website:
www.medipharmlabs.com
NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE
POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking
information” and “forward-looking statements” (collectively,
“forward-looking statements”) within the meaning of the applicable
Canadian securities legislation. All statements, other than
statements of historical fact, are forward-looking statements and
are based on expectations, estimates and projections as at the date
of this news release. Any statement that involves discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, assumptions, future events or performance (often but
not always using phrases such as “expects”, or “does not expect”,
“is expected”, “anticipates” or “does not anticipate”, “plans”,
“budget”, “scheduled”, “forecasts”, “estimates”, “believes” or
“intends” or variations of such words and phrases or stating that
certain actions, events or results “may” or “could”, “would”,
“might” or “will” be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. In this news release, forward-looking statements relate
to, among other things, statements regarding new product
development and commercialization, expected growth and the
establishment of operations in Australia. Forward-looking
statements are necessarily based upon a number of estimates and
assumptions that, while considered reasonable, are subject to known
and unknown risks, uncertainties, and other factors which may cause
the actual results and future events to differ materially from
those expressed or implied by such forward-looking statements. Such
factors include, but are not limited to: general business,
economic, competitive, political and social uncertainties; the
inability of MediPharm Labs to obtain adequate financing; the delay
or failure to receive regulatory approvals: and other factors
discussed in the Company’s filings, available on the SEDAR website
at www.sedar.com. There can be no assurance that such statements
will prove to be accurate, as actual results and future events
could differ materially from those anticipated in such statements.
Accordingly, readers should not place undue reliance on the
forward-looking statements and information contained in this news
release. Except as required by law, MediPharm Labs assumes no
obligation to update the forward-looking statements of beliefs,
opinions, projections, or other factors, should they change.
MediPharm Labs (TSXV:LABS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
MediPharm Labs (TSXV:LABS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024